Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial skin diseases; Gram-positive infections; Skin infections
- Focus Adverse reactions
- Sponsors Allergene
- 21 Aug 2017 Planned End Date changed from 30 Sep 2018 to 30 Jun 2018.
- 21 Aug 2017 Planned primary completion date changed from 1 Aug 2018 to 30 Jun 2018.
- 21 Aug 2017 Status changed from active, no longer recruiting to recruiting.